Effectiveness of radiotherapy and targeted radionuclide therapy for melanoma in preclinical mouse models: A combination treatments overview
Bull Cancer. 2023 Jun 3:S0007-4551(23)00216-3. doi: 10.1016/j.bulcan.2023.05.002. Online ahead of print.ABSTRACTCutaneous melanoma is an aggressive and highly metastatic skin cancer. In recent years, immunotherapy and targeted small-molecule inhibitors have improved the overall survival of patients. Unfortunately, most patients in advanced stages of disease exhibit either intrinsically resistant or rapidly acquire resistance to these approved treatments. However, combination treatments have emerged to overcome resistance, and novel treatments based on radiotherapy (RT) and targeted radionuclide therapy (TRT) have been deve...
Source: Bulletin du Cancer - June 5, 2023 Category: Cancer & Oncology Authors: Israel Lara-Vega Maximiliano V M Correa-Lara Armando Vega-L ópez Source Type: research
Safety profile of immune checkpoint inhibitors according to cancer type
CONCLUSION: Ipilimumab and history of autoimmune disease were both associated with the presence of grade≥2 irAEs and grade≥2 irAEs-free survival. The different cancer groups were not.PMID:37225616 | DOI:10.1016/j.bulcan.2023.04.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Chlo é Guérin Mathieu Laramas Fran çois Bettega Alexis Bocquet Elodie Berton Maxime Lugosi Laurence Bouillet Anne-Claire Toffart Source Type: research
Access and safety of dexamethasone in multiple myeloma patients
Bull Cancer. 2023 Jun;110(6):731-733. doi: 10.1016/j.bulcan.2023.05.001. Epub 2023 May 22.NO ABSTRACTPMID:37225617 | DOI:10.1016/j.bulcan.2023.05.001 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Florian Slimano Jean-Fran çois Tournamille Christophe Bardin Isabelle Madelaine Cyrille Hulin Philippe Moreau Catherine Rioufol Source Type: research
Safety profile of immune checkpoint inhibitors according to cancer type
CONCLUSION: Ipilimumab and history of autoimmune disease were both associated with the presence of grade≥2 irAEs and grade≥2 irAEs-free survival. The different cancer groups were not.PMID:37225616 | DOI:10.1016/j.bulcan.2023.04.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Chlo é Guérin Mathieu Laramas Fran çois Bettega Alexis Bocquet Elodie Berton Maxime Lugosi Laurence Bouillet Anne-Claire Toffart Source Type: research
Access and safety of dexamethasone in multiple myeloma patients
Bull Cancer. 2023 May 22:S0007-4551(23)00215-1. doi: 10.1016/j.bulcan.2023.05.001. Online ahead of print.NO ABSTRACTPMID:37225617 | DOI:10.1016/j.bulcan.2023.05.001 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Florian Slimano Jean-Fran çois Tournamille Christophe Bardin Isabelle Madelaine Cyrille Hulin Philippe Moreau Catherine Rioufol Source Type: research
Safety profile of immune checkpoint inhibitors according to cancer type
CONCLUSION: Ipilimumab and history of autoimmune disease were both associated with the presence of grade≥2 irAEs and grade≥2 irAEs-free survival. The different cancer groups were not.PMID:37225616 | DOI:10.1016/j.bulcan.2023.04.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Chlo é Guérin Mathieu Laramas Fran çois Bettega Alexis Bocquet Elodie Berton Maxime Lugosi Laurence Bouillet Anne-Claire Toffart Source Type: research
Access and safety of dexamethasone in multiple myeloma patients
Bull Cancer. 2023 May 22:S0007-4551(23)00215-1. doi: 10.1016/j.bulcan.2023.05.001. Online ahead of print.NO ABSTRACTPMID:37225617 | DOI:10.1016/j.bulcan.2023.05.001 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Florian Slimano Jean-Fran çois Tournamille Christophe Bardin Isabelle Madelaine Cyrille Hulin Philippe Moreau Catherine Rioufol Source Type: research
Safety profile of immune checkpoint inhibitors according to cancer type
CONCLUSION: Ipilimumab and history of autoimmune disease were both associated with the presence of grade≥2 irAEs and grade≥2 irAEs-free survival. The different cancer groups were not.PMID:37225616 | DOI:10.1016/j.bulcan.2023.04.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Chlo é Guérin Mathieu Laramas Fran çois Bettega Alexis Bocquet Elodie Berton Maxime Lugosi Laurence Bouillet Anne-Claire Toffart Source Type: research
Access and safety of dexamethasone in multiple myeloma patients
Bull Cancer. 2023 May 22:S0007-4551(23)00215-1. doi: 10.1016/j.bulcan.2023.05.001. Online ahead of print.NO ABSTRACTPMID:37225617 | DOI:10.1016/j.bulcan.2023.05.001 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Florian Slimano Jean-Fran çois Tournamille Christophe Bardin Isabelle Madelaine Cyrille Hulin Philippe Moreau Catherine Rioufol Source Type: research
Safety profile of immune checkpoint inhibitors according to cancer type
CONCLUSION: Ipilimumab and history of autoimmune disease were both associated with the presence of grade≥2 irAEs and grade≥2 irAEs-free survival. The different cancer groups were not.PMID:37225616 | DOI:10.1016/j.bulcan.2023.04.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Chlo é Guérin Mathieu Laramas Fran çois Bettega Alexis Bocquet Elodie Berton Maxime Lugosi Laurence Bouillet Anne-Claire Toffart Source Type: research
Access and safety of dexamethasone in multiple myeloma patients
Bull Cancer. 2023 May 22:S0007-4551(23)00215-1. doi: 10.1016/j.bulcan.2023.05.001. Online ahead of print.NO ABSTRACTPMID:37225617 | DOI:10.1016/j.bulcan.2023.05.001 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Florian Slimano Jean-Fran çois Tournamille Christophe Bardin Isabelle Madelaine Cyrille Hulin Philippe Moreau Catherine Rioufol Source Type: research
Safety profile of immune checkpoint inhibitors according to cancer type
CONCLUSION: Ipilimumab and history of autoimmune disease were both associated with the presence of grade≥2 irAEs and grade≥2 irAEs-free survival. The different cancer groups were not.PMID:37225616 | DOI:10.1016/j.bulcan.2023.04.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Chlo é Guérin Mathieu Laramas Fran çois Bettega Alexis Bocquet Elodie Berton Maxime Lugosi Laurence Bouillet Anne-Claire Toffart Source Type: research
Access and safety of dexamethasone in multiple myeloma patients
Bull Cancer. 2023 May 22:S0007-4551(23)00215-1. doi: 10.1016/j.bulcan.2023.05.001. Online ahead of print.NO ABSTRACTPMID:37225617 | DOI:10.1016/j.bulcan.2023.05.001 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Florian Slimano Jean-Fran çois Tournamille Christophe Bardin Isabelle Madelaine Cyrille Hulin Philippe Moreau Catherine Rioufol Source Type: research
Safety profile of immune checkpoint inhibitors according to cancer type
CONCLUSION: Ipilimumab and history of autoimmune disease were both associated with the presence of grade≥2 irAEs and grade≥2 irAEs-free survival. The different cancer groups were not.PMID:37225616 | DOI:10.1016/j.bulcan.2023.04.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Chlo é Guérin Mathieu Laramas Fran çois Bettega Alexis Bocquet Elodie Berton Maxime Lugosi Laurence Bouillet Anne-Claire Toffart Source Type: research
Access and safety of dexamethasone in multiple myeloma patients
Bull Cancer. 2023 May 22:S0007-4551(23)00215-1. doi: 10.1016/j.bulcan.2023.05.001. Online ahead of print.NO ABSTRACTPMID:37225617 | DOI:10.1016/j.bulcan.2023.05.001 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 24, 2023 Category: Cancer & Oncology Authors: Florian Slimano Jean-Fran çois Tournamille Christophe Bardin Isabelle Madelaine Cyrille Hulin Philippe Moreau Catherine Rioufol Source Type: research
